Regenerative medicine company encouraged by heart failure trial MedCity News Regenerative medicine company Juventas Therapeutics is touting the results from 12-month data of a phase 1 clinical trial of heart failure patients. At 12 months, heart failure patients treated with the company's stem cell therapy showed “significant” ... |
